Adlai Nortye (ANL) Stock Price, News & Analysis

Company Overview

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Key Stats

• Today's Range: $1.50 to $1.52
• 50-Day Range: $1.40 to $2.05
• 52-Week Range: $1.10 to $4.10
• Volume: 272 shs
• Average Volume: 12,138 shs
• Market Capitalization: $57.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Adlai Nortye Stock Analysis - MarketRank™

Adlai Nortye scored higher than 36% of companies evaluated by MarketBeat, and ranked 693rd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Adlai Nortye has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adlai Nortye has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adlai Nortye are expected to decrease in the coming year, from ($0.88) to ($0.92) per share.

Price to Book Value per Share Ratio

Adlai Nortye has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Adlai Nortye has been sold short.

Short Interest Ratio / Days to Cover

Adlai Nortye has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adlai Nortye has recently decreased by 36.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adlai Nortye does not currently pay a dividend.

Dividend Growth

Adlai Nortye does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Adlai Nortye has been sold short.

Short Interest Ratio / Days to Cover

Adlai Nortye has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adlai Nortye has recently decreased by 36.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adlai Nortye insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 35.21% of the stock of Adlai Nortye is held by institutions.

ANL Stock Analysis - Frequently Asked Questions

How have ANL shares performed this year?

Adlai Nortye's stock was trading at $2.69 at the start of the year. Since then, ANL shares have decreased by 41.8% and is now trading at $1.5660.

When did Adlai Nortye IPO?

Adlai Nortye (ANL) raised $58 million in an initial public offering (IPO) on Friday, September 29th 2023. The company issued 2,500,000 shares at a price of $23.00 per share.

How do I buy shares of Adlai Nortye?

Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adlai Nortye own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adlai Nortye investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), nCino (NCNO), Construction Partners (ROAD), Taiwan Semiconductor Manufacturing (TSM), XPeng (XPEV) and Cogent Communications (CCOI).

Company Calendar

• Today: 7/06/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANL
• Previous Symbol: NASDAQ:ANL
• CIK: 1944552
• Web: www.adlainortye.com
• Phone: 848-230-7430
• Fax: N/A
• Employees: 127
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +474.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 1.41
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 11.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 2.27

Miscellaneous

• Outstanding Shares: 36,900,000
• Free Float: N/A
• Market Cap: $57.79 million
• Optionable: Not Optionable
• Beta: -0.95